Although patients with BRAF-mutant melanoma with brain metastasis had fair local control on BRAF plus MEK inhibitors, the competing risk of death and distant intracranial and extracranial progression in our institutional experience was high. The gene discussed is MAP2K7; the disease is melanoma.